Relation between hyperuricemia and metabolic syndrome among obese women

Abstract EN

Bakgraound : Many studies found an association between hyperuricemia and blood pressure elevation, obesity and metabolic syndrome.

Methods and Subjects : The present study was conducted on 108 obese women to investigate the relationship between hyperuricemia and traditional cardiovascular risk factors including metabolic syndrome.

Women enrolled in the study did not have heart, liver or kidney disease, and were not on oral contraceptives, thiazides, loop diuretics, or low-dose aspirin.

After explaining the aim of the research and obtaining consent of the patients, personal and medical history were taken, blood pressure was measured, anthropometric measurements to calculate body mass index (BMI) and waist hip ratio (WHR) were done.

After an overnight fast, a venous blood sample was taken to assess serum uric acid, fasting blood glucose and serum lipid profile.

Hyperuricemia is defined as serum uric acid level ≥ 7 mg / dl (in men) or ≥ 6.0 mg / dl (in women).

Metabolic syndrome was defined using AHA / NHLBI (American Heart Association / National Heart, Lung, and Blood Institute) criteria.

Results : The present study showed that hyperuricemia was positively associated with systolic and diastolic blood pressure elevation, BMI, age, and serum triglycerides levels (TG), but negatively correlated to high density lipoprotein.

Hyperuricemia was an independent predictor to blood pressure elevation.

The diastolic and systolic blood pressure, HDL-C, age, and waist circumference were responsible for 59.1% of the serum uric acid variance.

It seemed that there is a mutual relationship between hyperuricemia and metabolic syndrome; each contributes to aggravation of the other.

Hyperuricemia which is an independent risk for cardiovascular disease may also be induced by medications for metabolic syndrome.

Conclusion : Serum uric acid level should be monitored in patients with metabolic syndrome and those at risk for coronary artery disease.

Since hyperuricemia is potentially modifiable, exclusion of hyperuricemic agents and inclusion of anti-uricemic measures in the dietary and therapeutic prophylactic regimens seems to carry better prognosis for patients at risk for developing cardiovascular disease